Publication: Relevance of cannabinoids in preclinical models of psychiatric disorders
dc.contributor.advisor | Soto Montenegro, Mª Luisa | |
dc.contributor.author | Lamanna Rama, Nicolás | |
dc.contributor.departamento | UC3M. Departamento de Bioingeniería | es |
dc.contributor.tutor | Desco Menéndez, Manuel | |
dc.date.accessioned | 2023-10-27T11:33:26Z | |
dc.date.available | 2023-10-27T11:33:26Z | |
dc.date.issued | 2023-09 | |
dc.date.submitted | 2023-09-28 | |
dc.description.abstract | Throughout this thesis, we are going to navigate through the history of cannabis, from its first use thousands of years ago, to its exponential growth in use and knowledge during the last third of the last century. The endocannabinoid system was a cutting-edge discovery, which initiated interest in cannabinoids both in their effects on the human body, and in their interaction with other neural systems, such as the dopaminergic reward system. Not much later, the implications of cannabis in adolescence were postulated, opening a wide range of possibilities in the study of cannabinoids. Consequently, researchers began to wonder whether cannabinoids might influence the consumption of other drugs and, the possible interactions with other endogenous systems, such as the opioid system, and their association with the onset of psychiatric disorders, such as schizophrenia. In this sense, preclinical models have provided a great impulse for the understanding of such processes and effects of cannabinoids. Nevertheless, it is important to note that the field of cannabinoid research is rapidly evolving, and although substantial progress has been made, many questions remain to be answered. | en |
dc.description.degree | Programa de Doctorado en Ciencia y Tecnología Biomédica por la Universidad Carlos III de Madrid | es |
dc.description.responsability | Presidente: Juan Nàcher Roselló.- Secretaria: Raquel Abalo Delgado.- Vocal: Miguel Ángel Morcillo Alonso | es |
dc.identifier.uri | https://hdl.handle.net/10016/38697 | |
dc.language.iso | eng | en |
dc.relation.haspart | https://doi.org/10.1016/j.euroneuro.2023.01.005 | |
dc.relation.haspart | https://doi.org/10.1038/s41598-022-08698-9 | |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.accessRights | open access | en |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject.eciencia | Biología y Biomedicina | es |
dc.subject.eciencia | Medicina | es |
dc.subject.other | Brain | en |
dc.subject.other | Adictions | en |
dc.subject.other | Metabolism | en |
dc.subject.other | Glucose | en |
dc.subject.other | Drugs withdrawal | en |
dc.subject.other | Neuroimaging | en |
dc.subject.other | Positron emission tomography | en |
dc.subject.other | X-Ray computed tomography | en |
dc.title | Relevance of cannabinoids in preclinical models of psychiatric disorders | en |
dc.type | doctoral thesis | * |
dspace.entity.type | Publication |
Files
Original bundle
1 - 2 of 2
Loading...
- Name:
- tesis_nicolas_lamanna_rama_2023.pdf
- Size:
- 4.84 MB
- Format:
- Adobe Portable Document Format
- Description:
No Thumbnail Available
- Name:
- tesis_nicolas_lamanna_rama_2023_version-integra.pdf
- Size:
- 6.38 MB
- Format:
- Adobe Portable Document Format
- Description:
- Versión íntegra y original de la tesis con material protegido por derechos de autor